Key result
Existing clinical trials of cyclooxygenase-2 inhibitors and traditional NSAIDs were underpowered and not designed to prospectively address cardiovascular safety, leaving their net effect uncertain.
Why the study?
Do cyclooxygenase-2 inhibitors and traditional NSAIDs increase cardiovascular risk?
Do cyclooxygenase-2 inhibitors and traditional NSAIDs increase cardiovascular risk?
The cardiovascular safety of coxibs and traditional NSAIDs remains uncertain due to underpowered existing trials, necessitating results from ongoing, purpose-designed, long-term clinical trials.
No takes yet. Share an insight, caveat, or question.
NSAID cardiovascular safety remains uncertain for clinical decisions; leaves open the need for dedicated prospective trials.
Hermann et al. (2007) conducted a review in Cardiovascular risk. Cyclooxygenase-2 inhibitors (coxibs) and traditional NSAIDs was evaluated on Cardiovascular events. Existing clinical trials of cyclooxygenase-2 inhibitors and traditional NSAIDs were underpowered and not designed to prospectively address cardiovascular safety, leaving their net effect uncertain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: